If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
GIP / GLP-1 / glucagon tri-agonist
Batch documentation
For investigational Retatrutide sourcing, review batch records, additional testing requirements, and destination-market requirements before pricing or recurring inventory planning.
Overview
Retatrutide (Eli Lilly's LY3437943) is an investigational 39-residue tri-agonist that engages GIP, GLP-1, and glucagon receptors in a single molecule. Adding the glucagon arm is what separates this asset from the GIP/GLP-1 dual agonists (Tirzepatide) and the GLP-1/glucagon dual agonists (Mazdutide, Survodutide); the glucagon component contributes hepatic energy expenditure on top of the incretin-driven glycaemic and satiety effects, and is the mechanistic reason for the unusually large weight-reduction deltas reported across the Phase 2 program. Vialdyne releases lyophilised Retatrutide acetate against a ≥99.0% main-peak HPLC specification, with a batch COA that includes RP-HPLC peak integration and ESI-MS identity, and Karl Fischer water and counter-ion quantitation available on request. For 503A and 503B compounding traffic and any downstream parenteral use, LAL endotoxin (USP <85>) and bioburden (USP <61>/<62>) are documented as add-on tests on the same lot, no re-sampling. Eight nominal strengths from 5 to 60 mg map onto both bench-scale aliquots and weekly dispensing inventories. Because aggregate world production volume for Retatrutide is still a fraction of what Semaglutide or Tirzepatide command, per-mg pricing is steeper at small quantities but normalises once a repeat order is locked against a defined synthesis route, ask for the 100 g and 1 kg tier sheet at the qualification stage.
Applications & buyer fit
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Supplied as a documented active in acetate counter-ion form by default; the buyer verifies current scheduling and compounding eligibility for the destination market.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Nasal spray listing · US inventory
Retatrutide is also listed in this catalog as a nasal spray solution.

Capsule listing
Retatrutide is also listed as a capsule product, dispatched within the United States from US inventory.

Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COARetatrutide 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 15 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 20 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 30 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 40 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 50 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 60 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COARetatrutide 100 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Third-party reportRetatrutide 50 mg
HPLC purity · MS identity
Third-party laboratory, Tianjin, China
Full, clear copy from sales
Customer-shared reportRetatrutide 20 mg
Purity · Content per vial
Janoshik (independent laboratory)
Full, clear copy from sales
Customer-shared reportRetatrutide 60 mg
Purity · Content per vial
Janoshik (independent laboratory)
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
Retatrutide remains investigational, still moving through clinical development, and has not been approved as a finished drug anywhere. We offer it as a pharmaceutical-grade active for research purposes and, in jurisdictions that permit it, for compounding-pharmacy use governed by the receiving pharmacy's quality system. Confirming that compounding is permitted under the destination market's prevailing regulatory posture rests with the buyer.
Selected literature
Frequently asked questions
The headline distinction is the glucagon receptor. Tirzepatide is a dual GIP/GLP-1 co-agonist; Retatrutide adds GCGR engagement, producing tri-mechanism activity. The glucagon arm contributes hepatic-energy-expenditure modulation that the dual class lacks, which in Phase 2 readouts has translated into larger weight-reduction magnitudes than any prior peptide in the metabolic space, including Tirzepatide at matched exposures. Both share a 39-residue scaffold and use C20 fatty-diacid lipidation for albumin-mediated half-life extension, but the receptor-binding determinants and the linker geometry diverge.
Investigational status governs everything. In any jurisdiction, the receiving pharmacy needs to confirm that an unapproved active can be compounded under their local rules, and that the patient-specific or batch-level documentation chain is intact. Three buyer profiles dominate current Retatrutide demand: translational and pre-clinical labs studying tri-agonist receptor pharmacology, 503A compounding pharmacies operating in permissive frameworks under physician prescription, and regulatory-track sponsors assembling IND or comparable submission packages. For the third group we can release the raw chromatograms and mass-spec data files alongside the COA so they drop directly into a CMC dossier.
Three drivers stack. First, world aggregate production volume is still small relative to the GLP-1 mono-agonists, so unit cost has not yet amortised. Second, the synthesis is more demanding, the longer SPPS run requires tighter purification cycles to clear deletion sequences that elute close to the target peak. Third, first-quote economics build in single-run synthesis cost rather than amortised repeat-run cost. Pricing improves materially at the 100 g and 1 kg break points and tightens further once a recurring schedule is locked against a defined route, so it is worth pricing both spot and 12-month commit at the qualification stage.
Yes. Retatrutide is listed as a nasal spray solution (5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg), filled in 10 mL or 20 mL bottles, with an MOQ of 10 bottles per content and fill. It is dispatched within the United States from US inventory; send an inquiry for current availability.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides